Table 2.
COVID-19 presentation and course.
| Treated | Untreated | |
|---|---|---|
| Number of subjects | 21 (100) | 42 (100) |
| Number of vaccine doses: median (IQR) | 3 (2–3) | 3 (2–3) |
| Time from last vaccine administration (days): median (IQR) | 150 (60–195) | 120 (38–210) |
| COVID-19 features | ||
| WHO class at presentation: median (IQR) | 1 (0–1) ** | 0 (0–1) |
| Symptoms at presentation | ||
| Dyspnoea: n (%) | 5 (24) | 3 (7) |
| Fever: n (%) | 13 (62) | 25 (60) |
| Upper Respiratory Symptoms: n (%) | 19 (90) | 34 (81) |
| GI symptoms: n (%) | 1 (5) | 2 (5) |
| Pneumonia: n (%) | 3 (14) | 3 (7) |
| COVID-19 course | ||
| Time to symptom resolution (days): median (IQR) | 5 (4–8) | 7 (3–8) |
| Time to viral clearance (days): median (IQR) | 10 (7–14) | 10 (7–14) |
| Any complication: n (%) | 1 (5) | 6 (14) |
| Hospitalisations: n (%) | 1 (5) | 0 (0) |
| Deaths: n (%) | 0 (0) | 1 (3) |
**: p < 0.010.